ERBB2 and gastric cancer: Regarding gastric cancer, our cohort yielded high-priority target recommendations for targeted therapy, such as MSI, Her2 expression, and PD-L1, while also uncovering rare but promising alterations such as ROS1 fusion and MET-amplifications.